RNAC · CIK 1453687
What Cartesian Therapeutics, Inc. told the SEC could break it.
Cartesian Therapeutics' disclosures describe a clinical-stage cell-therapy company whose value rests on unproven programs. It has never earned product revenue — only collaboration and license income — and won't until it gains FDA approval and commercializes a candidate such as its lead autologous mRNA cell therapy, Descartes-08. Its patient-by-patient therapies are produced at a single main cGMP facility in Frederick, Maryland that it also intends to use for commercial supply, so a disruption there would impair the pipeline, and commercialization hinges on the FDA's BLA review (whose timelines aren't always met) and on drug-pricing pressure such as most-favored-nation policy.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- single main cGMP manufacturing facility in Frederick, Marylandmedium
Cartesian's autologous (patient-by-patient) cell therapies are produced at a single main cGMP manufacturing facility in Frederick, Maryland that it intends to also use for commercial supply, so disruption at that one site would impair its pipeline.
“Our main manufacturing facility is located in Frederick, Maryland, and operates under current good manufacturing practice, or cGMP. This facility has sufficient capacity to support current clinical needs and can potentially transition to support commercial manufacturing of our maturing pipeline of innovative cell therapies”
SEC filing →As of 2026
Regulatory & policy
- FDA BLA approval process and drug-pricing (most-favored-nation) policymedium
Cartesian's commercialization depends on FDA BLA approval (with PDUFA review timelines the FDA does not always meet), and federal drug-pricing actions pressing most-favored-nation pricing could pressure future product economics.
“The Administration has warned that manufacturers that fail to make “significant progress” toward MFN pricing will face enumerated regu”
SEC filing →As of 2026
Other disclosures
- clinical-stage, no product revenue; dependent on candidate approval (Descartes-08)low
Cartesian has never generated product revenue (only collaboration/license revenue) and will not until it obtains regulatory approval and commercializes a candidate such as its lead autologous mRNA cell therapy Descartes-08 — concentrating its value in unproven clinical programs.
“We will not generate significant revenue from product sales unless and until we obtain regulatory approval and commercialize one of our current or future product candidates.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Astellas Pharma Inc.
“Amounts paid and remaining obligations with regard to the Xork product candidate not reimbursed by Astellas through the Astellas Agreement were subject to potential reimbursement through deductions to CVR distributions”
Cited →Swedish Orphan Biovitrum (Sobi)
“In June 2020, we entered into the Sobi License. Sobi paid us a one-time, upfront payment of $75.0 million, and upon the closing of a private placement of our common stock to Sobi at a price of $138.468 per share, we received an additional $25.0 million from Sobi. We are eligible to receive $630.0 million in milestone payments upon the achievement of various development and regulatory milestones and sales thresholds for annual net sales of NASP, and tiered royalty payments ranging”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch